"[T]he PBMTA [S 127] contains numerous problematic provisions ... This legislation was drafted without the input or priorities of employers, who sponsor health benefit plans for more than 155 million Americans, and who are the primary customers of PBMs.... PBMTA's language can be interpreted to erode the protections ERISA provides ... Rather than attempt to mandate or pressure 'point-of-sale rebates,' Congress should work to end the rebate system, and achieve actual and transparent drug prices.... While PBMTA does include limited language requiring transparency from PBMs, this language is wholly inadequate."

MORE >>